FB-EVAR for the treatment of CAAA has undergone significant evolution over the past decades and continues to advance, representing a promising and increasingly viable approach to this disease.
Tesheiner et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: